Great question Fuzzy ... more risk on the front end means more upside on the back end usually. To get something you have to give something.

And as an investor, if you want to skate at $5-10 asap then a heftier front end is your goal. If you want a bigger number on the back end and have the time and patience then maybe less up front and a slower grow?

Also, what about the bargaining chip of the library? How will that play into the equation? That should have a hefty price tag also, especially as it gets closer and closer to looking like epigenetics is truly at te door step ready to "arrive" ... with an entry approaching approval.

So what does BP REALLY want? Just apabetalone for DM/CVD/CKD? - this by itself is a tasty market and number. The whole enchilada, and full library of "futures"?

If I were RVX I would want an awful lot on the front end for an orchestrated deal for the whole enchilada, and just handing over the keys. On the other hand there is still Zenith. And/or a deal for just apabetalone thus opening the door with credibility for the star factory and other future deals if BP wants to limit risk now but be a foreseable/preferred "close" developmental partner.

Just so many ways it could go, and realistically much of it has probably been mostly decided at this stage with a new study with a BTD looming ... and patent life ticking ...

... there is probably somebody with an apabetalone patent clock ticking away dollars for every day in remaining patent life that passes without sales ...